fulvestrant has been researched along with azd2014 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bigley, G; Bihani, T; Chresta, CM; Cosulich, SC; Curwen, J; D'Cruz, CM; Davies, BR; Delpuech, O; Green, S; Grondine, M; Guichard, SM; Howard, Z; Klinowska, T; McEwen, R; Pass, M; Pike, KG; Polanska, UM; Yates, JW | 1 |
1 other study(ies) available for fulvestrant and azd2014
| Article | Year |
|---|---|
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Estradiol; Female; Fulvestrant; HEK293 Cells; Humans; Immunoblotting; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Morpholines; Multiprotein Complexes; Protein Kinase Inhibitors; Pyrimidines; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |